[Comment] β-agonists for ARDS: the dark side of adrenergic stimulation?

Source: The Lancet

In The Lancet, Fang Gao Smith and the BALTI-2 study investigators report the findings of their phase-3 randomised trial of intravenous salbutamol for acute respiratory distress syndrome (ARDS). The trial, based on reliable preclinical evidence and an encouraging phase-2 trial, was stopped early because of safety concerns.

View the original article

Login or register to help identify topics from this page.

This page may contain content contributed by CPNP members or aggregated from other online sources. This content is provided as an unmoderated service to members for civil discussion and collaboration. Any opinions, conclusions, or recommendations are those of the author. If you come across any abuse or violation of the terms of use, please report the abuse.